

- Abdolmaleky HM, Thiagalingam S, Wilcox M.* Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. *Am J Pharmacogenomics* 2005; 5: 149-60.
- Abel T, Zukin RS.* Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. *Curr Opin Pharmacol* 2008; 8: 57-64.
- Albert PR, Benkelfat C, Descarries L.* The neurobiology of depression-revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms. *Philos Trans R Soc Lond B Biol Sci* 2012; 367: 2378-81.
- Ambler Z.* Základy neurologie. Praha: Galén, 2011; 351 s.
- Anisman H, Merali Z, Hayley S.* Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. *Prog Neurobiol* 2008; 85: 1-74.
- Ariel IM.* Tumors of the peripheral nervous system. *CA Cancer J Clin* 1983; 33: 282-99.
- Azevedo FA, Carvalho LR, Grinberg LT, Farfel JM, Ferretti RE, Leite RE, Jacob Filho W, Lent R, Herculano-Houzel S.* Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. *J Comp Neurol* 2009; 513: 532-41.
- Babenko O, Kovalchuk I, Metz GA.* Epigenetic programming of neurodegenerative diseases by an adverse environment. *Brain Res* 2012; 1444: 96-111.
- Banks WA, Erickson MA.* The blood-brain barrier and immune function and dysfunction. *Neurobiol Dis* 2010; 37: 26-32.
- Bartko D, Drobný M.* Neurologia. Martin: Osveta, 1991; 710 s.
- Bate L, Gardiner M.* Molecular genetics of human epilepsies. *Expert Rev Mol Med* 1999; 1999: 1-22.
- Belmaker RH, Agam G.* Major depressive disorder. *N Engl J Med* 2008; 358: 55-68.
- Benetín J, Valkovič P.* Parkinsonova choroba. Bratislava: Herba, 2009; 224 s.
- Biasini E, Turnbaugh JA, Unterberger U, Harris DA.* Prion protein at the crossroads of physiology and disease. *Trends Neurosci* 2012; 35: 92-103.
- Blennow K, de Leon MJ, Zetterberg H.* Alzheimer's disease. *Lancet* 2006; 368: 387-403.
- Botto LD, Moore CA, Khoury MJ, Erickson JD.* Neural-tube defects. *N Engl J Med* 1999; 341: 1509-19.
- Bradley WG, Daroff RB, Marsden CD, Fenichel GM.* Neurology in clinical practice. Philadelphia: Butterworth-Heinemann, 2004; 2545 s.



- Bray NJ, Leweke FM, Kapur S, Meyer-Lindenberg A. The neurobiology of schizophrenia: new leads and avenues for treatment. *Curr Opin Neurobiol* 2010; 20: 810-5.
- Brott T, Bogousslavsky J. Treatment of acute ischemic stroke. *N Engl J Med* 2000; 343: 710-22.
- Buckner JC, Brown PD, O'Neill BP, Meyer FB, Wetmore CJ, Uhm JH. Central nervous system tumors. *Mayo Clin Proc* 2007; 82: 1271-86.
- Cami J, Farre M. Drug addiction. *N Engl J Med* 2003; 349: 975-86.
- Coppede F, Mancuso M, Siciliano G, Migliore L, Murri L. Genes and the environment in neurodegeneration. *Biosci Rep* 2006; 26: 341-67.
- Copstead LC, Banasik JL. Pathophysiology. St. Louis: Saunders, 2009; 1392 s.
- De Keyser J, Mostert JP, Koch MW. Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. *J Neurol Sci* 2008; 267: 3-16.
- Dieška D, Badalík L, Šašinka M. *Vademecum Medici*. Martin: Osveta, 1998; 1824 s.
- Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. *Brain Struct Funct* 2008; 213: 93-118.
- Fleiss B, Gressens P. Tertiary mechanisms of brain damage: a new hope for treatment of cerebral palsy? *Lancet Neurol* 2012; 11: 556-66.
- Fredericks CM, Lisa K, Saladin LK. Pathophysiology of the motor systems: principles and clinical presentations. Davis, 1996; 594 s.
- Freedman R. Schizophrenia. *N Engl J Med* 2003; 349: 1738-49.
- Freeman R. Autonomic peripheral neuropathy. *Lancet* 2005; 365: 1259-70.
- Geldmacher DS, Whitehouse PJ. Evaluation of dementia. *N Engl J Med* 1996; 335: 330-6.
- Ginsberg MD, Busto R. Rodent models of cerebral ischemia. *Stroke* 1989; 20: 1627-42.
- Goldstein DS. Adrenal responses to stress. *Cell Mol Neurobiol* 2010; 30: 1433-40.
- Greenamyre JT. Huntington's disease-making connections. *N Engl J Med* 2007; 356: 518-20.
- Greenberg DA, Jin K. Regenerating the brain. *Int Rev Neurobiol* 2007; 77: 1-29.
- Gusella JF, MacDonald ME. Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. *Nat Rev Neurosci* 2000; 1: 109-15.
- Gutierrez M, Merino JJ, de Lecinana MA, Diez-Tejedor E. Cerebral protection, brain repair, plasticity and cell therapy in ischemic stroke. *Cerebrovasc Dis* 2009; 27 Suppl 1: 177-86.
- Haberland C. Clinical neuropathology: text and color atlas. New York: Demos Medical Publishing, 2006; 320 s.
- Hamilton JP. Epigenetics: principles and practice. *Dig Dis* 2011; 29: 130-5.
- Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. *Neuropsychopharmacology* 2012; 37: 137-62.
- Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. *Altern Med Rev* 2006; 11: 294-329.
- Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. *Nat Rev Neurosci* 2002; 3: 291-301.



- Hemmer B, Kieseier B, Cepok S, Hartung HP. New immunopathologic insights into multiple sclerosis. *Curr Neurol Neurosci Rep* 2003; 3: 246-55.
- Hindmarch I. Expanding the horizons of depression: beyond the monoamine hypothesis. *Hum Psychopharmacol* 2001; 16: 203-18.
- Höschl C, Libiger J, Švestka J. *Psychiatrie*. Praha: Tigris, 2004; 884 s.
- Hughes RA, Cornblath DR. Guillain-Barre syndrome. *Lancet* 2005; 366: 1653-66.
- Hurley RA, Flashman LA, Chow TW, Taber KH. The brainstem: anatomy, assessment, and clinical syndromes. *J Neuropsychiatry Clin Neurosci* 2010; 22: 1-7.
- Huttner HB, Schwab S. Malignant middle cerebral artery infarction: clinical characteristics, treatment strategies, and future perspectives. *Lancet Neurol* 2009; 8: 949-58.
- Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. *Annu Rev Neurosci* 2006; 29: 565-98.
- Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. *Neurochem Int* 2004; 45: 583-95.
- Insel TR. Rethinking schizophrenia. *Nature* 2010; 468: 187-93.
- Jirák R, Koukolík F. *Demence*. Praha: Galén, 2004; 335 s.
- Johnston MV, Fatemi A, Wilson MA, Northington F. Treatment advances in neonatal neuroprotection and neurointensive care. *Lancet Neurol* 2011; 10: 372-82.
- Kábrt J, Valach V. *Stručný lékařský slovník*. Martin: Osveta, 1992; 480 s.
- Kadaňka Z. *Učebnice speciální neurologie*. Brno: Masarykova univerzita, 2010; 301 s.
- Kahler SG, Fahey MC. Metabolic disorders and mental retardation. *Am J Med Genet C Semin Med Genet* 2003; 117C: 31-41.
- Kato T. Molecular neurobiology of bipolar disorder: a disease of 'mood-stabilizing neurons'? *Trends Neurosci* 2008; 31: 495-503.
- Knight JA. *Genetics and inherited conditions*. Salem Press, 2010; 1236 s.
- Koob GF, Le Moal M. Addiction and the brain antireward system. *Annu Rev Psychol* 2008; 59: 29-53.
- Koob GF, Sanna PP, Bloom FE. Neuroscience of addiction. *Neuron* 1998; 21: 467-76.
- Krishnadas R, Cavanagh J. Depression: an inflammatory illness? *J Neurol Neurosurg Psychiatry* 2012; 83: 495-502.
- Krishnan V, Nestler EJ. Linking molecules to mood: new insight into the biology of depression. *Am J Psychiatry* 2010; 167: 1305-20.
- Kukumberg P a kol. *Skica panické poruchy*. *Neurologie pro praxi* 2003; 6: 312-4.
- Kukumberg P, Novotný V, Provazník V, Žucha I. *Neurologicko-psychiatrické záchvatové stavy*. Bratislava: Herba, 1998; 152 s.
- Lang AE, Lozano AM. Parkinson's disease. First of two parts. *N Engl J Med* 1998a; 339: 1044-53.
- Lang AE, Lozano AM. Parkinson's disease. Second of two parts. *N Engl J Med* 1998b; 339: 1130-43.
- Lanpher B, Brunetti-Pierri N, Lee B. Inborn errors of metabolism: the flux from Mendelian to complex diseases. *Nat Rev Genet* 2006; 7: 449-60.
- Levy PA. Inborn errors of metabolism: part 1: overview. *Pediatr Rev* 2009; 30: 131-7.
- Li SH, Li XJ. Huntingtin and its role in neuronal degeneration. *Neuroscientist* 2004; 10: 467-75.



- Lietzau G, Kowianski P, Karwacki Z, Dziewiatkowski J, Witkowska M, Sidor-Kaczmarek J, Morys J. The molecular mechanisms of cell death in the course of transient ischemia are differentiated in evolutionary distinguished brain structures. *Metab Brain Dis* 2009; 24: 507-23.
- Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. *N Engl J Med* 1994; 330: 613-22.
- Lott IT, Dierssen M. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. *Lancet Neurol* 2010; 9: 623-33.
- Mabbott NA, MacPherson GG. Prions and their lethal journey to the brain. *Nat Rev Microbiol* 2006; 4: 201-11.
- Mareska M, Gutmann L. Lambert-Eaton myasthenic syndrome. *Semin Neurol* 2004; 24: 149-53.
- Martin JB. Molecular basis of the neurodegenerative disorders. *N Engl J Med* 1999; 340: 1970-80.
- McDonald JW, Sadowsky C. Spinal-cord injury. *Lancet* 2002; 359: 417-25.
- Micieli G, Tosi P, Marcheselli S, Cavallini A. Autonomic dysfunction in Parkinson's disease. *Neurol Sci* 2003; 24 Suppl 1: S32-4.
- Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. *Annu Rev Neurosci* 2005; 28: 57-87.
- Moore KL, Dalley AF, Agur AMR. Clinically oriented anatomy. Philadelphia: Lippincott Williams & Wilkins, 2009; 1168 s.
- Moreno-De-Luca A, Ledbetter DH, Martin CL. Genetic [corrected] insights into the causes and classification of [corrected] cerebral palsies. *Lancet Neurol* 2012; 11: 283-92.
- Morimoto RI. Stress, aging, and neurodegenerative disease. *N Engl J Med* 2006; 355: 2254-5.
- Morton PG, Fontaine DK. Critical care nursing: a holistic approach. Philadelphia: Lippincott Williams & Wilkins, 2008; 1408 s.
- Motlova L, Koukolik F. Schizofrenie. Neurobiologie, klinický obraz, terapie. Praha: Galén, 2004; 437 s.
- Mucke L. Neuroscience: Alzheimer's disease. *Nature* 2009; 461: 895-7.
- Mueser KT, McGurk SR. Schizophrenia. *Lancet* 2004; 363: 2063-72.
- Mumenthaler M, Mattle H. Fundamentals of neurology: an illustrated guide. New York: Thieme, 2005; 304 s.
- Nestler EJ. Is there a common molecular pathway for addiction? *Nat Neurosci* 2005; 8: 1445-9.
- Nevšímalová S, Růžička E, Tichý J a kol. Neurologie. Praha: Galén, 2005; 367 s.
- Nguyen MD, Julien JP, Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration? *Nat Rev Neurosci* 2002; 3: 216-27.
- North SH, Shriver-Lake LC, Taitt CR, Ligler FS. Rapid analytical methods for on-site triage for traumatic brain injury. *Annu Rev Anal Chem (Palo Alto Calif)* 2012; 5: 35-56.
- Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. *N Engl J Med* 2000; 343: 938-52.
- O'Shea M. Cerebral palsy. *Semin Perinatol* 2008; 32: 35-41.



- Palop JJ, Chin J, Mucke L.* A network dysfunction perspective on neurodegenerative diseases. *Nature* 2006; 443: 768-73.
- Pascuzzi RM.* Myasthenia gravis and Lambert-Eaton syndrome. *Ther Apher* 2002; 6: 57-68.
- Pečeňák J a kol.* Kapitoly o schizofrénii. Martin: Osveta, 2005; 196 s.
- Perry VH.* The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. *Brain Behav Immun* 2004; 18: 407-13.
- Pietrobon D, Striessnig J.* Neurobiology of migraine. *Nat Rev Neurosci* 2003; 4: 386-98.
- Plata-Salaman CR.* Brain cytokines and disease. *Acta Neuropsychiatrica* 2002; 4: 262-78.
- Porth CM.* Pathophysiology: concepts of altered health states. Philadelphia: Lippincott Williams & Wilkins, 2004; 1616 s.
- Praško J.* Úzkostné poruchy: klasifikace, diagnostika a léčba. Praha: Portál, 2005; 416 s.
- Prusiner SB.* Shattuck lecture-neurodegenerative diseases and prions. *N Engl J Med* 2001; 344: 1516-26.
- Ptak C, Petronis A.* Epigenetic approaches to psychiatric disorders. *Dialogues Clin Neurosci* 2010; 12: 25-35.
- Querfurth HW, LaFerla FM.* Alzheimer's disease. *N Engl J Med* 2010; 362: 329-44.
- Qureshi IA, Mehler MF.* Advances in epigenetics and epigenomics for neurodegenerative diseases. *Curr Neurol Neurosci Rep* 2011; 11: 464-73.
- Ramachandran VS.* Encyclopedia of the human brain. San Diego: Academic Press, 2002; 3454 s.
- Reddy PH, Williams M, Tagle DA.* Recent advances in understanding the pathogenesis of Huntington's disease. *Trends Neurosci* 1999; 22: 248-55.
- Reeves AG, Swenson RS.* Disorders of the nervous system: A primer. <http://www.dartmouth.edu/~dons/index.html>, 2008.
- Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, Obeso JA.* Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. *Lancet Neurol* 2009; 8: 1128-39.
- Rogan S, Lippa CF.* Alzheimer's disease and other dementias: a review. *Am J Alzheimers Dis Other Demen* 2002; 17: 11-7.
- Ropper A, Samuels M.* Adams and Victor's Principles of neurology. New York: McGraw-Hill Professional, 2005; 1384 s.
- Roth BL, Sheffler DJ, Kroeze WK.* Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. *Nat Rev Drug Discov* 2004; 3: 353-9.
- Rubinsztein DC.* The roles of intracellular protein-degradation pathways in neurodegeneration. *Nature* 2006; 443: 780-6.
- Sacks O.* Migréna. Praha: Dybbuk, 2012; 439 s.
- Seidl Z, Obenberger J.* Neurologie pro studium i praxi. Praha: Grada, 2004; 362 s.
- Shin LM, Liberzon I.* The neurocircuitry of fear, stress, and anxiety disorders. *Neuropsychopharmacology* 2010; 35: 169-91.
- Schloesser RJ, Huang J, Klein PS, Manji HK.* Cellular plasticity cascades in the



- pathophysiology and treatment of bipolar disorder. *Neuropsychopharmacology* 2008; 33: 110-33.
- Schmahmann JD*. Disorders of the cerebellum: ataxia, dysmetria of thought, and the cerebellar cognitive affective syndrome. *J Neuropsychiatry Clin Neurosci* 2004; 16: 367-78.
- Schwab JM, Brechtel K, Mueller CA, Failli V, Kaps HP, Tuli SK, Schluesener HJ*. Experimental strategies to promote spinal cord regeneration-an integrative perspective. *Prog Neurobiol* 2006; 78: 91-116.
- Siegel GJ, Albers RW, Brady ST, Price DL*. Basic neurochemistry: molecular, cellular, and medical aspects. San Diego: Elsevier Academic Press, 2006; 1016 s.
- Soros P, Whitehead S, Spence JD, Hachinski V*. Antihypertensive treatment can prevent stroke and cognitive decline. *Nat Rev Neurol* 2013; *in press*.
- Spillane J, Beeson DJ, Kullmann DM*. Myasthenia and related disorders of the neuromuscular junction. *J Neurol Neurosurg Psychiatry* 2010; 81: 850-7.
- Taninishi H, Takeda T, Sasaki T, Shiraishi K, Morita K*. Ketamine decreased ischemic neuronal damage by shortening the duration of ischemic depolarization; quantitative evaluation in gerbils. *J Cerebral Blood Flow Metab* 2009; 29: S421-S2.
- Tsankova N, Renthal W, Kumar A, Nestler EJ*. Epigenetic regulation in psychiatric disorders. *Nat Rev Neurosci* 2007; 8: 355-67.
- Tyrer P, Baldwin D*. Generalised anxiety disorder. *Lancet* 2006; 368: 2156-66.
- Urdinguio RG, Sanchez-Mut JV, Esteller M*. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. *Lancet Neurol* 2009; 8: 1056-72.
- van den Pol AN*. Viral infections in the developing and mature brain. *Trends Neurosci* 2006; 29: 398-406.
- van Os J, Kapur S*. Schizophrenia. *Lancet* 2009; 374: 635-45.
- Varsik P a kol.* Nervový systém II. Patogenéza a klinika nervových chorôb. Bratislava: Lufema, 1999; 651 s.
- Verity C, Firth H, ffrench-Constant C*. Congenital abnormalities of the central nervous system. *J Neurol Neurosurg Psychiatry* 2003; 74 Suppl 1: i3-8.
- Vialou V, Feng J, Robison AJ, Nestler EJ*. Epigenetic mechanisms of depression and antidepressant action. *Annu Rev Pharmacol Toxicol* 2013; 53: 59-87.
- Volterra A, Meldolesi J*. Astrocytes, from brain glue to communication elements: the revolution continues. *Nat Rev Neurosci* 2005; 6: 626-40.
- Wartenberg KE, Schmidt JM, Mayer SA*. Multimodality monitoring in neurocritical care. *Crit Care Clin* 2007; 23: 507-38.
- Zuvich RL, McCauley JL, Pericak-Vance MA, Haines JL*. Genetics and pathogenesis of multiple sclerosis. *Semin Immunol* 2009; 21: 328-33.